---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089913"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T08:59:44.282194+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio Q2 net loss $0.44/share; cash $12.1M; AD & PD trial data positive

## Summary
- Q2 2024 net loss $0.44 per share vs $1.07 YoY; operating expenses $7.8M (R&D $5.8M, G&A $2.0M).
- Cash $4.0M at June 30, 2024; increased to $12.1M as of Aug 14 via warrant exercises and ELOC.
- Phase 2/3 AD study: 3.3-point ADAS-Cog11 improvement vs 0.3 placebo; effective in APOE4 carriers; no ARIA.
- Phase 3 PD study: improvements in MDS-UPDRS and cognition; halted cognitive decline in all patients.
- New crystalline buntanetap patent filed; FDA OK for phase 3 with crystal form; US patent for TBI; team expanded.

## SEC filing metadata
- accession: 0001104659-24-089913
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924089913/0001104659-24-089913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924089913/tm2421776d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089913
- JSON: https://secwatch.observer/filing/0001104659-24-089913.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089913.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.